CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03152708

Enrollment

Registered

2017-05-15

Start date

2017-11-01

Completion date

2017-12-31

Last updated

2017-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Brief summary

This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Chinese nationality * No limits on Gender and age * First diagnosed GBM * Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic glioblastoma, WHO level IV)

Exclusion criteria

* Other types of glioma by histological diagnosis * Tumor tissue not eligible for the central laboratory testing standard * No enough tumor tissue for the central laboratory test

Design outcomes

Primary

Measure	Time frame
CD95 Ligand Positive Rate	0 day

Secondary

Measure	Time frame
CpG2 Positive Rate	0 day

Contacts

Primary ContactJack Hou

jhou@canbridgepharma.com00862152996609

Outcome results